Announcements Trials
Browse Landscape

Phase

Phase 1/2 1Phase 1 1

Status

Withdrawn 1Completed 1

Sponsor Class

NIH 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 25Thoracic 3Sarcoma 2Head & Neck 2Gynecologic 2Breast 2Genitourinary 1CNS 1

Conditions

Squamous Cell Carcinoma of Head and Neck 168Head and Neck Neoplasms 150Carcinoma, Squamous Cell 33Neoplasm Metastasis 18Laryngeal Neoplasms 17Colorectal Neoplasms 17Tongue Neoplasms 16Neoplasms 16Mouth Neoplasms 16Recurrence 14Oropharyngeal Neoplasms 14Carcinoma, Non-Small-Cell Lung 14Salivary Gland Neoplasms 12Hypopharyngeal Neoplasms 11Carcinoma 11Laryngeal Diseases 10Breast Neoplasms 10Nasopharyngeal Carcinoma 9Pancreatic Neoplasms 6Neoplasms, Squamous Cell 6Sarcoma 5Pharyngeal Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 5Colonic Neoplasms 5Carcinoma, Renal Cell 5Stomach Neoplasms 4Rectal Neoplasms 4Ovarian Neoplasms 4Melanoma 4Lymphoid Interstitial Pneumonia 4

Interventions

pembrolizumab 20Docetaxel 8Carboplatin 8Fluorouracil 6Cisplatin 6Nivolumab 5fludarabine 4Trastuzumab 4Paclitaxel 4Magnetic Resonance Spectroscopy 4Gemcitabine 4Cyclophosphamide 4Biopsy 4Bevacizumab 4fludarabine phosphate 3durvalumab 3atezolizumab 3Taxes 3Radiotherapy 3Polymerase Chain Reaction 3Gene Expression Profiling 3Capecitabine 3Albumin-Bound Paclitaxel 3ulixertinib 2tisotumab vedotin 2spartalizumab 2belinostat 2adavosertib 2X-Rays 2Vorinostat 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Esophageal Neoplasms × Cetuximab × Head & Neck × Clear all
NCT04464967 2021-05-12

Safety and Preliminary Efficacy of SNK01 in Combination With Trastuzumab or Cetuximab in Subjects With Advanced HER2 or EGFR Cancers

NKGen Biotech, Inc.

Phase 1/2 Withdrawn
BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Esophageal Neoplasms, Neoplasm Metastasis, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Recurrence, Sarcoma, Stomach Neoplasms, Colorectal Neoplasms, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT00397384 2015-09-30

Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer

National Cancer Institute (NCI)

Phase 1 Completed
43 enrolled
CNSGastrointestinalHead & NeckSarcomaThoracic

Squamous Cell Carcinoma of Head and Neck, Anus Neoplasms, Appendiceal Neoplasms, Bile Duct Neoplasms, Carcinoma, Non-Small-Cell Lung, Colonic Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Rectal Neoplasms, Salivary Gland Neoplasms, Stomach Neoplasms, Tongue Neoplasms, Esthesioneuroblastoma, Olfactory, Gastrointestinal Stromal Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡